Skip to content

Mutation-driven structural and functional changes in ACE2 and their potential implications for Alzheimer's disease.

Aug 2026 · Journal of Biomolecular Structure and Dynamics · pp. 1-22 · 0 citations · 38 references
Medicine

TL;DR

Mechanistic insights are provided into how ACE2 polymorphisms may disrupt protein stability and impair angiotensin II recognition, offering a computational basis for understanding their potential contribution to Alzheimer's disease susceptibility and supporting future experimental validation.

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by complex molecular mechanisms extending beyond amyloid-β aggregation and tau pathology. Increasing evidence implicates dysregulation of the renin-angiotensin system in AD, with angiotensin-converting enzyme 2 (ACE2) playing a critical regulatory role. However, the structural and functional consequences of ACE2 genetic polymorphisms in Alzheimer's disease remain insufficiently explored. In this study, a comprehensive in silico framework was employed to investigate the impact of ACE2 missense variants on protein stability, dynamics, and interaction with angiotensin II. Missense single nucleotide polymorphisms (SNPs) were retrieved from the dbSNP and gnomAD databases and annotated using the Ensembl Variant Effect Predictor. A multi-tiered screening strategy integrating SIFT, PANTHER, PhD-SNP, SNPs&GO, FoldX, DynaMut2, and mCSM was applied. Based on consensus predictions, four high-risk variants (F308S, L186S, Y654S, and L570S) were selected for structural analysis. Molecular dynamics simulations revealed that all selected variants induced varying degrees of structural destabilization compared to wild-type ACE2 protein. Mutant proteins exhibited increased backbone deviation, enhanced residue-level flexibility, reduced compactness, elevated solvent exposure, weakened intramolecular interactions, broader conformational sampling, and reduced energetic stability. The L570S showing the most pronounced effects, increased structural fluctuations, reduced complex stability and progressively weaker binding free energies. Protein-peptide docking demonstrated reduced interaction scores for angiotensin II across all mutant variants. Overall, this study provides mechanistic insights into how ACE2 polymorphisms may disrupt protein stability and impair angiotensin II recognition, offering a computational basis for understanding their potential contribution to Alzheimer's disease susceptibility and supporting future experimental validation.

View source

Similar papers

Open access Sep 2026

APOE-stratified genome-wide association analyses provide insights into the genetic etiology of Alzheimers’s disease

Understanding of the genetic architecture of AD in the context of its main genetic driver is improved, and APOE-stratified insights may help understand and overcome side effects, inform clinical trial enrollment strategies, and create the scientific basis for targeted, mechanism-driven therapies in neurodegenerative di...

J. Thomassen, H. Leonard, Brittany Ulms et al. · 0 citations
Oct 2026

B-325 APOE Genetic Testing and E4 Allele Frequency in a Clinical Population: Implications for Alzheimer’s Disease Risk Stratification

Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder worldwide and represents a major public health challenge driven by population aging. It is estimated that more than 50 million people currently live with dementia, with AD accounting for 60–70% of cases, and projections exceeding 150 millio...

F. Mattesco, M. Souza, Jorge Borges et al. · 0 citations
Review Open access Oct 2026

Polygenic Risk Scores in Alzheimer’s Disease: A Cross-Scale View from Genes to Brain and Behavior

Alzheimer’s disease (AD) is a genetically complex disorder in which inherited susceptibility is distributed across rare high-impact variants, the apolipoprotein E (APOE) locus, and a broad polygenic background of common risk alleles. Polygenic risk scores (PRSs) provide a quantitative framework for summarizing this dis...

Efthalia Angelopoulou, Ioannis Stamelos, Stefanos N. Sampatakakis et al. · 0 citations
Review Open access Oct 2026

Emerging therapeutic strategies to target APOE4 in Alzheimer's disease.

The apolipoprotein E ε4 (APOE4) allele is the strongest common genetic risk factor for late-onset Alzheimer's disease. However, its incomplete penetrance supports the view that it acts as a modifiable systems-level perturbation of brain homeostasis rather than a deterministic driver. Increasing evidence further positio...

Wei I. Jiang, Bing-Ying Wang, Deng-Ke K. Ma · 0 citations
Open access Jul 2026

Correlations of PSEN1, PSEN2, and APP missense variants on the production of Aβ peptides against variant effect prediction

Abstract INTRODUCTION Early‐onset Alzheimer's disease (EOAD) is mostly caused by mutations in presenilin‐1/2 (PSEN1, PSEN2) and amyloid precursor protein (APP) genes. Both genetic and experimental evidence have supported the PSEN‐APP amyloid hypothesis as the leading pathogenesis of Alzheimer's disease (AD). Thus far,...

Jiyeon Song, Serina Yan, Sophia Liu et al. · 0 citations
Review Open access Sep 2026

Missense mutations in the SNCA gene: Molecular mechanisms and clinical implications.

The molecular architecture of the SNCA gene is outlined, including regulatory regions, alternative splicing, and untranslated regions that influence αSyn expression and isoform diversity, and seven missense mutations of the SNCA gene are discussed in detail from the genomic level, extending to phenotypic presentations.

Pranaya Gade, Nishant Patel, J. P. Rissardo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.